CERUS CORP (CERS) competitors & alternatives
Health Care · NASDAQ
CERUS CORP (CERS)'s top competitors and alternatives — its most similar public companies — include HAEMONETICS CORP (HAE), Bio-Rad Laboratories (BIO), VOR BIOPHARMA INC (VOR), CRISPR THERAPEUTICS AG (CRSP), JANUX THERAPEUTICS INC (JANX), PROKIDNEY CORP CLASS A (PROK), CABALETTA BIO INC (CABA), ARTIVA BIOTHERAPEUTICS INC (ARTV), KYVERNA THERAPEUTICS INC (KYTX), LINEAGE CELL THERAPEUTICS INC (LCTX), PROTARA THERAPEUTICS INC (TARA) and MaxCyte, Inc. (MXCT). These are CERUS CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top CERS competitors & alternatives
-
HAEMONETICS CORPHAEHealth Care
Haemonetics provides automated plasma collection systems, blood processing devices, and hospital blood management technologies serving plasma centers, blood…
$78.03 (as of 2026-07-22) · market cap $3.5B
-
Bio-Rad LaboratoriesBIOHealth Care
A multinational life science and clinical diagnostics company providing research tools, diagnostic test systems, and consumables to laboratories and…
$305.96 (as of 2026-07-22) · market cap $8.2B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
CRISPR THERAPEUTICS AGCRSPHealth Care
CRISPR Therapeutics develops gene-editing medicines using CRISPR/Cas9 technology, with the first approved CRISPR therapy (CASGEVY) for sickle cell disease and…
$47.24 (as of 2026-07-22) · market cap $4.6B
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.62 (as of 2026-07-22) · market cap $953M
-
PROKIDNEY CORP CLASS APROKHealth Care
ProKidney is pioneering a first-in-class autologous kidney cell therapy to slow kidney function decline in advanced CKD and diabetes patients, currently in…
$1.53 (as of 2026-07-22) · market cap $462M
-
CABALETTA BIO INCCABAHealth Care
Cabaletta Bio is a clinical-stage biotechnology firm developing one-time, curative CAR T cell therapies aimed at resetting the immune system for patients with…
$2.75 (as of 2026-07-22) · market cap $449M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.02 (as of 2026-07-22) · market cap $487M
-
KYVERNA THERAPEUTICS INCKYTXHealth Care
Kyverna is a clinical-stage immunology biotech developing novel investigational therapeutics with no approved products and complete dependence on successful…
$7.40 (as of 2026-07-22) · market cap $452M
-
LINEAGE CELL THERAPEUTICS INCLCTXHealth Care
Lineage Cell Therapeutics develops allogeneic cell therapy treatments for serious human diseases through its AlloSCOPE™ manufacturing platform and partnerships…
$1.11 (as of 2026-07-22) · market cap $278M
-
PROTARA THERAPEUTICS INCTARAHealth Care
Clinical-stage biopharmaceutical company developing TARA-002, a cell therapy based on an established immunopotentiator, and IV Choline Chloride for oncology,…
$4.08 (as of 2026-07-22) · market cap $229M
-
MaxCyte, Inc.MXCTHealth Care
MaxCyte enables cell therapy development through proprietary electroporation technology that delivers molecules into cells for engineering next-generation…
$1.14 (as of 2026-07-22) · market cap $125M
Not quite? Describe exactly what you want →
Peers are CERUS CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: CERUS CORP (CERS).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.